Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials

類似資料

• Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
  著者:: Ascierto, Paolo Antonio, 等
  出版事項: (2020)
• Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
  著者:: Wolchok, J.D., 等
  出版事項: (2017)
• Correction: Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
  出版事項: (2020)
• A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
  著者:: Dummer, Reinhard, 等
  出版事項: (2015)
• Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg
  著者:: Grimaldi, Antonio M, 等
  出版事項: (2014)